Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A double-blind, randomized, placebo controlled dose-escalating phase 1 study to evaluate the safety and immunogenicity of a MVA HIV-1 vaccine administered by three different routes and at three different dosage levels in HIV-uninfected healthy volunteers at lower risk of infection.

Proposed period of release:
01/02/2004 to 28/02/2005

Name of the Institute(s) or Company(ies)
International AIDS Vaccine Initiative, New York, USA, New York, USA;

3. Is the same GMO release planned elsewhere in the Community?
United Kingdom;

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Modified vaccinia virus Ankara-based anti-HIV vaccine (MVA.HIVA)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Cowpox vaccinia virusOrthopoxvirusvaccinia virusAnkara

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known